Overview

Eliquis Regulatory Post Marketing Surveillance (rPMS)

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effectiveness information about Eliquis in general practice
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Apixaban
Criteria
Inclusion Criteria:

- Signed data release

- Patients undergoing elective total hip replacement arthroplasty or elective total knee
replacement arthroplasty

Exclusion Criteria:

- Being treated for an indication not approved for the use of Eliquis® in Korea

- Is contraindicated for the use of Eliquis® as described in the Korean label